Global Market for Vaccines Worth $36.3 Billion by 2013

Thu Jan 24, 2008 8:58am EST

* Reuters is not responsible for the content in this press release.

WELLESLEY, Mass.--(Business Wire)--According to a new technical market research report, VACCINE
(, the global market for vaccines will be worth
$22.4 billion in 2008. This is expected to increase to $36.3 billion
by 2013, a compound average annual growth rate (CAGR) of 10.1%.

   The market is broken down into applications of human and
veterinary or animal vaccines. Of these, human vaccines have the
largest share of the market. Expected to be worth $18.7 billion in
2008, this segment should reach $31.3 billion by 2013, for a CAGR of
10.9%. Pediatric vaccines have been the leading human vaccine segment,
traditionally. However, adult and therapeutic vaccines are likely to
usurp this position in the near future.

   While some time ago manufacturers were seen quitting this arena
due to a limited portfolio of products with narrowing margins, there
has been a paradigm shift in the economics and centers of
manufacturing. Large multinational participants are now concentrating
on developing and marketing proprietary human vaccines that are not
limited by pricing concerns in developed nations. The public supply of
undifferentiated routine and immunization vaccines is now the primary
domain of local regional players from countries such as China, India
and Korea. This has led to a burgeoning of the revenues and pipeline
of adult and therapeutic vaccines such as those for various cancers,
and combination vaccines.

   The veterinary vaccine segment is expected to reach almost $3.8
billion in 2008. By 2013, it should reach $5 billion, for a CAGR of
5.9%. Veterinary vaccines remain an almost orphan market, closed to
academic and scientific research in spite of the immense scope it

   Patent activity, however, has heightened to almost frenzied levels
in the study period. The American and European patent offices have
accepted patents in all areas of vaccine discovery, relating to both
human and animal vaccines amounting to as many as 250 each year for
2006 as well as 2007. This is also reflected in the clinical trial
activity that has shown a similar trend. Almost 80 trials in various
stages are in progress for both prophylactic and therapeutic AIDS

   Among the most notable technological breakthroughs in this area
are DNA-related vaccines. These represent an immense improvement over
traditional vaccines in terms of immune response, stability and
production scalability.

                    ($ MILLIONS)

Vaccine        2003     2008     2013    2008-2013
------------ -------- -------- -------- ------------
Human         6,380    18,685   31,300      10.9
------------ -------- -------- -------- ------------
Veterinary    2,000    3,750    5,000       5.9
------------ -------- -------- -------- ------------
Total         8,380    22,435   36,300      10.1
------------ -------- -------- -------- ------------

Source: BCC Research

Target Date: January 2008                        Electronic PDF: $4850

   Data and analysis extracted from this press release must be
accompanied by a statement identifying BCC Research
(, 40 Washington Street, Suite 110, Wellesley, MA;
Telephone: 866-285-7215, as the source and
publisher, along with report number, which can be found immediately
after the report title. Thank you.

BCC Research
Dawn Peters, 978-489-7301 x603
Fax: 781-489-7308
Additional Releases:

Copyright Business Wire 2008